Table 2.

Treatment-related adverse events occurring at any grade in ≥ 5% of patients or grade ≥ 3 in any patient

N = 168	Any grade	Grades 1–2	Grade 3	Grade 4	Grade 5
Any event, n (%)	115 (68.5)	92 (54.8)	16 (9.5)	5 (3.0)	2 (1.2)
Fatigue	32.9 (19.0)	29 (17.3)	3 (1.8)	0	0
Infusion-related reaction	24 (14.3)	24 (14.3)	0	0	0
Nausea	22 (13.1)	22 (13.1)	0	0	0
Diarrhea	15 (8.9)	15 (8.9)	0	0	0
Arthralgia	13 (7.7)	12 (7.1)	1 (0.6)	0	0
Decreased appetite	12 (7.1)	12 (7.1)	0	0	0
Influenza-like illness	11 (6.5)	11 (6.5)	0	0	0
Dyspnea exertional	5 (3.0)	4 (2.4)	1 (0.6)	0	0
Elevated AST	4 (2.4)	3 (1.8)	1 (0.6)	0	0
Elevated GGT	4 (2.4)	1 (0.6)	1 (0.6)	2 (1.2)	0
Anemia	3 (1.8)	0	2 (1.2)	1 (0.6)	0
Autoimmune hepatitis	3 (1.8)	0	3 (1.8)	0	0
Elevated ALT	3 (1.8)	2 (1.2)	1 (0.6)	0	0
Hypoxia	3 (1.8)	2 (1.2)	1 (0.6)	0	0
Pneumonitis	3 (1.8)	2 (1.2)	1 (0.6)	0	0
Axillary pain	2 (1.2)	1 (0.6)	1 (0.6)	0	0
Thrombocytopenia	2 (1.2)	1 (0.6)	0	1 (0.6)	0
Acute hepatic failure	1 (0.6)	0	0	0	1 (0.6)
Cardiac arrest	1 (0.6)	0	0	1 (0.6)	0
Hypertriglyceridemia	1 (0.6)	0	1 (0.6)	0	0
Hypokalemia	1 (0.6)	0	0	1 (0.6)	0
Neutropenia	1 (0.6)	0	0	1 (0.6)	0
Neutrophil count decreased	1 (0.6)	0	1 (0.6)	0	0
Noncardiac chest pain	1 (0.6)	0	1 (0.6)	0	0
Pleuritic pain	1 (0.6)	0	1 (0.6)	0	0
Proteinuria	1 (0.6)	0	1 (0.6)	0	0
Pulmonary arterial hypertension	1 (0.6)	0	1 (0.6)	0	0
Respiratory distress	1 (0.6)	0	0	0	1 (0.6)
Respiratory failure	1 (0.6)	0	0	1 (0.6)	0

ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transferase